EUVIMEDEUVIMED entdecken
Crossref

A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development

Pingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, Chengqing Wu, Miaomiao Ge

Contemporary Clinical Trials · 2023

DOI: 10.1016/j.cct.2023.107119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2023. Verfasst von Pingye Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA. Electronic address: pingyezhangusc@gmail.com. Hauptthemen laut MEDLINE: Research Design, Medical Oncology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a recent article, Zhang et al. proposed a 2-in-1 adaptive design to seamlessly expand a selected dose, based on efficacy compared to the control arm, from a Phase 2 trial to a Phase 3 trial for oncology drug development. In this article, we communicate a variation of the proposed design which selects a dose to expand based on direct comparison of high dose to low dose when both doses demonstrate promising efficacy compared to the control arm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignMedical OncologyHumansDrug DevelopmentDose-Response Relationship, DrugClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

2-in-1 adaptive designDose optimization, seamless phase 2/3 trialOncology

Autor:innen und Institutionen

  • Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA. Electronic address: pingyezhangusc@gmail.com.
  • Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA.
  • Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA.

Zitieren

APA

Zhang, P., Li, X. N., Lu, K., Wu, C., & Ge, M. (2023). A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2023.107119

Vancouver

Zhang P, Li XN, Lu K, Wu C, Ge M. A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development. Contemporary Clinical Trials. 2023. doi:10.1016/j.cct.2023.107119

BibTeX
@article{Zhang2023,
  author = {Zhang, Pingye and Li, Xiaoyun Nicole and Lu, Kaifeng and Wu, Chengqing and Ge, Miaomiao},
  title = {A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development},
  journal = {Contemporary Clinical Trials},
  year = {2023},
  doi = {10.1016/j.cct.2023.107119}
}
Kostenlos starten →